Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2023-05-24 4:52 pm Sale | 13D | VectivBio Holding AG VECT | ORBIMED ADVISORS LLC | 5,156,561 7.7% | -1,557,000![]() (-23.19%) | View |
2023-05-24 4:47 pm Purchase | 13D | Prelude Therapeutics Incorporated PRLD | ORBIMED ADVISORS LLC | 15,716,642 28.6% | 869,565![]() (+5.86%) | View |
2023-05-17 4:46 pm Sale | 13D | SpringWorks Therapeutics, Inc. SWTX | ORBIMED ADVISORS LLC | 4,178,588 6.7% | -806,412![]() (-16.18%) | View |
2023-05-16 4:28 pm Unchanged | 13D | Fusion Pharmaceuticals Inc. FUSN | ORBIMED ADVISORS LLC | 2,930,670 4.6% | 0 (Unchanged) | View |
2023-05-16 4:25 pm Sale | 13D | Verona Pharma plc VRNA | ORBIMED ADVISORS LLC | 3,777,778 4.8% | -482,913![]() (-11.33%) | View |
2023-05-08 5:01 pm Purchase | 13D | Kinnate Biopharma Inc. KNTE | ORBIMED ADVISORS LLC | 7,559,729 16.2% | 1,460,932![]() (+23.95%) | View |
2023-05-05 11:14 am Unchanged | 13D | Xtant Medical Holdings, Inc. XTNT | ORBIMED ADVISORS LLC | 73,114,592 67.1% | 0 (Unchanged) | View |
2023-05-02 7:28 pm Purchase | 13D | Kinnate Biopharma Inc. KNTE | ORBIMED ADVISORS LLC | 6,098,797 13.1% | 1,405,168![]() (+29.94%) | View |
2023-04-21 5:03 pm Sale | 13D | TELA Bio, Inc. TELA | ORBIMED ADVISORS LLC | 2,866,267 11.9% | -192,000![]() (-6.28%) | View |
2023-04-11 7:10 pm Purchase | 13D | Apollomics Inc. | ORBIMED ADVISORS LLC | 662,561 10.3% | 662,561![]() (New Position) | View |
2023-04-07 4:38 pm Sale | 13D | Galecto, Inc. GLTO | ORBIMED ADVISORS LLC | 2,696,654 10.5% | -74,790![]() (-2.70%) | View |
2023-03-31 4:48 pm Purchase | 13D | Gracell Biotechnologies Inc. GRCL | ORBIMED ADVISORS LLC | 7,583,576 11.2% | 1,612,904![]() (+27.01%) | View |
2023-03-29 5:24 pm Unchanged | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,619,135 13.4% | 0 (Unchanged) | View |
2023-03-24 4:57 pm Unchanged | 13D | CalciMedica Inc. GRAY | ORBIMED ADVISORS LLC | 297,380 5.4% | 0 (Unchanged) | View |
2023-03-24 4:43 pm Sale | 13D | 89bio, Inc. ETNB | ORBIMED ADVISORS LLC | 0 0% | -1,504,436![]() (Position Closed) | View |
2023-03-22 4:27 pm Sale | 13D | CalciMedica Inc | ORBIMED ADVISORS LLC | 297,380 18.9% | -3,865,967![]() (-92.86%) | View |
2023-03-14 4:19 pm Purchase | 13D | Theseus Pharmaceuticals, Inc. THRX | ORBIMED ADVISORS LLC | 17,233,668 39.6% | 395,000![]() (+2.35%) | View |
2023-02-28 5:09 pm Sale | 13D | Fusion Pharmaceuticals Inc. FUSN | ORBIMED ADVISORS LLC | 2,930,670 4.7% | -67,311![]() (-2.25%) | View |
2023-02-28 4:00 pm Purchase | 13D | Enliven Therapeutics Inc. IMRA | ORBIMED ADVISORS LLC | 8,949,339 21.8% | 8,949,339![]() (New Position) | View |
2023-02-23 3:23 pm Purchase | 13D | Kinnate Biopharma Inc. KNTE | ORBIMED ADVISORS LLC | 4,693,629 10.6% | 1,295,700![]() (+38.13%) | View |